laboratori corpor
remain bullish lh follow solid mark decent core lab trend
strong cro growth launchpad progress importantli in-lin volum
relat contract chang guidanc pama pressur
step view launchpad initi partial off-set see
opportun acceler share gain addit patient access effort
progress financi flexibl remain high expect on-going strong
trend covanc continu like lh strateg posit reiter
buy rais target ep vs prior
volum contract chang in-lin result help assuag
concern lab trend look solid referr hospitals/health system
partner increas novemb level impress organ growth
covanc januari lab volum met manag expect
follow buy aet buy contract
chang addit recent renew contract wrap
sizabl manag care contract negoti forese futur
provid solid price visibl continu view diagnost lab
busi key driver signific portion healthcar decis
near-term challeng pama view lh
meaning diversif covanc high quality/low cost offer
net revenu in-lin expect organ
growth acquisit contribut partial off-set
divestitur advers fx translat adjust ebit also
in-lin impact pama higher labor cost off-set strong
trend covanc launchpad save drive in-lin margin
adjust ep three cent ahead modestli better
line item
impress revenu cc organ despit bp
advers fx translat valu covanc comprehens platform
reson client differenti offer lh outpac
market speed patient recruit covanc support
fda approv new drug evidenc success end-to-end
servic offer addit segment expand margin impress
bp strong organ demand launchpad save exit
tr target
laboratori corpor america hold
year ttm book-to-bil net order backlog approach
expect convert revenu next month lh robust platform data
analyt capabl uniqu patient access virtual trial coupl attract pharma/
biotech fund level expect continu strong trend covanc forese futur
lab result solid diagnost revenu touch ahead think strhe
top line yoy tie busi disposit pama fx
advers weather one less revenu day exclud item organ
revenu organ volum increas revenu per requisit declin
ex-disposit adjust oper incom margin expect phase ii
launchpad initi allevi margin pressur expect save year
oper effici digit facil optim improv custom experi
lastli hospital/health system referr rebound decemb soft novemb level
compani continu see attract opportun increment partnership expect market
pressur drive potenti uptick partnership opportun industri particip
struggl on-going market pressur
cater consum labcorp continu progress consum access/conveni
initi plan roll-out increment labcorp walgreen locat end
least locat next four year compani seen encourag result
exist locat volum growth attract nps/custom satisfact feedback see
opportun expand healthcar servic offer creat one stop shop consum
addit continu see attract opportun around compani self-collect devic
given increment access user conveni expect lh suit digit solut labcorp
labcorp pre-check labcorp patient drive on-going oper improv patient
satisfact time
trend strong expect on-going deploy cffo
roughli in-lin think despit payment tie disposit forens
test busi addit lh repurchas stock bod author new
repurchas program share net ebitda ratio financi
flexibl remain high compani expect gener continu
expect lh augment core growth on-going capit deploy pama pressur step
think acceler potenti target like
guidanc solid estim updat lh provid full year guidanc larg
bracket expect includ consolid revenu growth vs strhe
diagnost revenu growth vs strhe covanc revenu growth
 vs strhe adjust ep vs strhe fine
tune adjust ep estim reiter buy rate
page
laboratori corpor america hold
servic
revenu
incom equiti invest
revenu
laboratori corpor america mm
page
laboratori corpor america hold
headquart burlington nc laboratori corpor america hold labcorp one
largest independ clinic laboratori broad offer includ routin test
blood chemistri urinalys pap hiv substance-abus etc specialti test oncolog hiv
genotyp phenotyp diagnost genet clinic research trial compani also
oper cro busi extend servic offer includ clinic research provid
meaning intern presenc recent chiltern acquisit expand cro servic
clinic lab remain integr part healthcar deliveri model diagnost test critic
compon treatment decis process combin covanc busi lh boast
signific scale divers servic offer uniqu posit area person medicin
potenti risk-bas reimburs system diversifi revenu stream custom
base also meaning lower reimburs risk one custom repres revenu
govern pay addit signific clinic horsepow geograph
diversif provid platform addit growth opportun time
valuat risk
price target base stock trade adjust ep slight discount
current multipl given labcorp sizabl esoter presenc solid cash flow gener
attract cross-sel opportun covance/chiltern view appropri addit
believ effici initi aggress focu cost control could provid
support risk rate price target includ advers shift reimburs pama poor
integr acquisit pressur econom uncertainti perform covanc
compani mention note
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
